| US 7,511,056 B2 | ||
| TGF-β inhibitors | ||
| Clive Gideon Diefenbacher, Greenwood, Ind. (US); Thomas Albert Engler, Indianapolis, Ind. (US); Hong-Yu Li, Zionsville, Ind. (US); Sushant Malhotra, Los Altos, Calif. (US); Jason Scott Sawyer, Indianapolis, Ind. (US); and Yan Wang, Carmel, Ind. (US) | ||
| Assigned to Eli Lilly and Company, Indianapolis, Ind. (US) | ||
| Appl. No. 11/577,094 PCT Filed Nov. 02, 2005, PCT No. PCT/US2005/039554 § 371(c)(1), (2), (4) Date Apr. 12, 2007, PCT Pub. No. WO2006/052568, PCT Pub. Date May 18, 2006. |
||
| Claims priority of provisional application 60/626545, filed on Nov. 10, 2004. | ||
| Prior Publication US 2008/0262004 A1, Oct. 23, 2008 | ||
| Int. Cl. A01N 43/42 (2006.01); A61K 31/44 (2006.01); C07D 491/02 (2006.01); C07D 498/02 (2006.01); C07D 401/00 (2006.01) | ||
| U.S. Cl. 514—300 [514/338; 546/121; 546/276.7] | 4 Claims |
1. A compound of Formula I:
 n is 1-2;
R1 is hydrogen or C1-C4 alkyl;
R2 is selected from the group consisting of 1-H-pyrrolo[2,3-b]pyridine, 1-H-pyrrolo[2,3-c]pyridine, 1-H-pyrazolo[3,4-b]pyridine,
and 7-H-pyrrolo[2,3-d]pyrimidine all of which may be optionally substituted with C1-C4 alkyl or phenyl;
and the pharmaceutically acceptable salts thereof.
|